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Abstract
Glioblastoma (GBM), the most aggressive and most common form of primary brain tumor, has a median survival of 12–15
months. Surgical excision, radiation and chemotherapy are rarely curative since tumor cells broadly disperse within the
brain. Preventing dispersal could be of therapeutic benefit. Previous studies have reported that increased cell-cell cohesion
can markedly reduce invasion by discouraging cell detachment from the tumor mass. We have previously reported that
a5b1 integrin-fibronectin interaction is a powerful mediator of indirect cell-cell cohesion and that the process of fibronectin
matrix assembly (FNMA) is crucial to establishing strong bonds between cells in 3D tumor-like spheroids. Here, we explore a
potential role for FNMA in preventing dispersal of GBM cells from a tumor-like mass. Using a series of GBM-derived cell lines
we developed an in vitro assay to measure the dispersal velocity of aggregates on a solid substrate. Despite their similar
pathologic grade, aggregates from these lines spread at markedly different rates. Spreading velocity is inversely
proportional to capacity for FNMA and restoring FNMA in GBM cells markedly reduces spreading velocity by keeping cells
more connected. Blocking FNMA using the 70 KDa fibronectin fragment in FNMA-restored cells rescues spreading velocity,
establishing a functional role for FNMA in mediating dispersal. Collectively, the data support a functional causation between
restoration of FNMA and decreased dispersal velocity. This is a first demonstration that FNMA can play a suppressive role in
GBM dispersal.
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Introduction
Glioblastoma (GBM) is the most common and most malignant
primary brain tumor with a median survival of 12-months [1,2].
GBM represents 60% of all gliomas and 30% of all intracranial
tumors [3]. The hallmark of these aggressive tumors is their ability
to rapidly disperse into surrounding brain tissue. Despite aggressive
surgical intervention, directed radiation therapy, and systemic
chemotherapy,mediansurvivalremainspoor. RecentdatafromUS
and European cancer registries report median survival rates in
GBM patients of less than 30% at one year, 5% at three years, and
3% at five years [4]. Good prognostic factors include young age at
diagnosis (,50 years old), initial Karnofsky Performance Score
.80, the extent of resection [5], and low Survivin and Ki-67
expression [6]. Hypermethylation of the MGMT promoter is also
generally considered to correlate with good prognosis [7] and a
favorable response to chemotherapy by alkylating agents [8].
GBM is lethal partly due to its propensity for early microscopic
dispersal prior to diagnosis, confounded by the practical
improbability of a complete resection including all microscopic
tumor remnants. Accordingly, gliomas almost always recur, and in
90% of patients, recurrence is often within 2 to 3 cm from the
border of the original lesion [9]. This local dispersal generally
leads to very poor clinical outcome [10]. Thus, preventing tumor
cell dispersal would be of significant therapeutic benefit.
Cytokines [11], lymphokines [12,13], various adhesion mole-
cules [14], growth factors[15], metalloproteases [16,17], calcium-
activated proteases such as calpain-2 [18], and a myriad of
extracellular matrix components [14] have been identified as
potential regulators of brain tumor invasion. However, no single
factor can be regarded as a ‘‘master switch,’’ and the process is
likely a dynamic interplay between multiple components. There-
fore, a more global parameter of brain tumor behavior is necessary
to understand the effects of various contributors to the equilibrium
between the invasive and noninvasive states. A critical component
of this equilibrium is the ability of tumor cells to remain adherent
to one another, rather than to invade and infiltrate the
surrounding tissue. We have previously reported that increased
cell-cell cohesion can markedly reduce invasion in several cancer
models including human lung cancer [19], fibrosarcoma [20], and
glioma cell lines [21]. Thus, increasing cell-cell cohesion could, in
principle, represent a possible strategy of discouraging detachment
of cells from the tumor mass and subsequent dispersal.
Cell-cell cohesion can be regulated by several cell surface adhesion
molecules, including cadherins and integrins. Cadherins are a large
family of calcium-dependent cell surface adhesion molecules and are
thought to be the principal mediators of direct intercellular cohesion
[22]. Cadherins have been linked with transition to malignancy of a
variety of tumors. Most notably, E-cadherin has been implicated as
beingan important moleculeininvasion and metastasisofcarcinoma,
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with tumor aggressiveness [23]. However, a general survey of the
literature indicates that downregulation of cadherin expression is not
alwaysassociatedwithincreasedinvasiveness.Forexample,cadherin-
dependent adhesion, rather than discouraging cell migration, appears
to promote cell adhesion, neurite outgrowth and overall migratory
capacity of human U373-MG glioblastoma cells [24]. Moreover,
even if cadherin expression could be manipulated to increase
cohesion in GBM, this method would be cumbersome, requiring
up-regulation of cadherin expression by an in vivo gene-transfer
strategy. Ideally, in the best interest of safety and efficacy,
upregulation of cell-cell cohesion in GBM should be induced
pharmacologically.
The synthetic glucocortocoid dexamethasone (Dex), has been
demonstrated to reactivate the ability of cells to assemble
fibronectin into a complex fibrous matrix through a process
termed fibronectin matrix assembly (FNMA) [25,26]. We have
previously shown that a5b1-fibronectin interaction can mediate
strong intercellular cohesion of CHO cells when grown as three-
dimensional aggregates [27] and that this extracellular matrix-
mediated cohesion is largely dependent on the ability of cells to
assemble fibronectin into a matrix [28]. FNMA has been
extensively studied in many cancer models, however, relatively
little is known in regard to its potential role in glioblastomas. A
recent study reported that malignant gliomas demonstrate
increased staining of fibronectin matrix that distinguish them
from normal brain tissue and that interfering with matrix assembly
can render tumors more susceptible to chemotherapy, suggesting a
role for FNMA in brain tumor biology [29]. We previously showed
that Dex increases cohesion and decreases invasion of glioblasto-
ma cells [21]. We therefore reasoned that Dex treatment may
represent a potential strategy for modulating FNMA in glioblas-
toma cells and that, in principle, this should decrease the rate at
which tumor cells detach from and escape the tumor mass. We
exploited the fact that glioblastoma cells form three-dimensional
spheres when placed in hanging drop culture. We then developed
a method of quantifying the spreading velocity of these aggregates
when plated onto tissue culture plastic, in much the same way as a
‘‘wetting’’ phenomenon observed for ordinary liquids as they
interact with a substrate [30]. We also explored the relationship
between spreading velocity and FNMA.
Materials and Methods
Cell lines
The malignant astrocytoma cell lines U87-MG, U118-MG and
LN-229 were obtained from the American Type Culture
Collection (ATCC, Manassas, VA). U87-MG cells were main-
tained in Eagle’s Minimum Essential Medium (ATCC, Manassas,
VA) containing 10% fetal bovine serum (FBS, Hyclone, Logan,
UT), 2 mM L-glutamine, 1 mM sodium pyruvate, 0.1 mM
nonessential amino acids, and 1.5 g/L sodium bicarbonate
(Gibo-BRL, NY). U118-MG and LN-229 cells were maintained
in Dulbecco’s Modified Eagle’s Medium (Gibco-BRL, NY)
containing 10% and 5% fetal bovine serum, respectively, 4 mM
L-glutamine, 4.5 g/l glucose, and 1.5 g/l sodium bicarbonate. All
media were supplemented with 100 mg/ml streptomycin sulfate,
100 U/ml penicillin G sodium, 0.25 mg/ml amphotericin B, and
50 mg/ml gentamicin sulfate (Gibco-BRL, NY). All cell lines were
maintained at 37uC, 95% humidity, and 5% CO2.
Aggregate preparation
Near-confluent cell monolayers were dissociated from 10-cm
tissue culture plates with 0.05% trypsin/0.53 mM EDTA (TE).
Dispersed cells were washed in complete medium to inhibit the
trypsin then centrifuged to pellet the cells. Pellets were washed with
PBS and resuspended in complete medium to a concentration of
1610
6 cells/ml. Ten-ml aliquots were deposited on the underside of
the lid of a 10-cm tissue culture dish. The bottom of the dish
contained 5-ml of PBS and served to prevent evaporation of the
drops by forming a hydration chamber. Hanging drops were
created by inverting the lid over the hydration chamber. The drops
were incubated at 37uC, 95% humidity, and 5% CO2 for 24–
48 hours, allowing cells to coalesce and form spherical aggregates.
Measurement of aggregate dispersal velocity
A single aggregate was plated into a 35 mm tissue culture plate
containing pre-warmed CO2-independent medium with 10%
FBS. The plate was then transferred to a heated microscope stage
of a Nikon Eclipse TE-300 microscope equipped with a
Photometrics Coolsnap ES B&W digital camera and connected
to an Apple G4 computer running IPLab imaging software (Exton,
PA). Aggregates were allowed to adhere to the plates for
15 minutes, whereupon images were captured every 5 minutes
for up to 8 hours. Images were analyzed using ImageJ software.
Aggregate diameter was measured at 4 different points and
averaged. Diameter measured at t0 was used to normalize each
subsequent image time-point. The normalized diameter was then
plotted as a function of time. The relationship between aggregate
diameter and time was analyzed by linear regression. Regression
lines for which the correlation coefficient, r
2, was greater than 0.95
were used to calculate dispersal velocity from the slope. Between
10 and 15 aggregates were used to generate each data set.
Treatment of cells with FNMA-inducing agents
Fifty-thousand cells were plated into wells of a 24-well tissue
culture plate and incubated in complete medium until cells
reached 80% confluence. Adhering cells were then washed once
with PBS then incubated in medium containing either 10
26 M
Dex (Sigma, St. Louis, MO), 25 mM MEK inhibitor (MEKi) PD
98059 (Calbiochem, Gibbstown, NJ), or 0.5 mM Geldanamycin
(GA, Calbiochem, Gibbstown, NJ) for 24 hours. For carrier
controls, cells were incubated in either sterile distilled H2O (for
Dex) or DMSO (for MEKi and GA). Control and treated cells
were either utilized to generate aggregates for measurement of
dispersal velocity as described above, or were assessed for their
ability to assemble a fibronectin matrix.
Assessment of FNMA by immunofluorescence
Adherent cells were blocked in CAS-Block (Invitrogen,
Carlsbad, CA) for 30 minutes. Fibronectin matrix was detected
by incubating cells in anti-FN antibody (ab6584, Abcam, Cam-
bridge, MA) for 1 hour at room temperature (RT). After 3 washes
with HBSS cells were incubated in Alexafluor-568 secondary
antibody (Invitrogen, Carlsbad, CA) for 30 minutes. After several
washes in HBSS, cells were incubated in Syto-16 nuclear stain
(Invitrogen, Carlsbad, CA) for 15 minutes and mounted in
FluorSave reagent (Calbiochem, Gibbstwon, NJ). Cells were
visualized using fluorescence microscopy on a Nikon Eclipse
TE300 inverted microscope. Images from red and green channels
were captured using a Photometrics Coolsnap ES digital camera
connected to an Apple G4 computer, assigned false color, and
merged in IPLab imaging software.
Aggregate compaction assay
Cells were trypsinized, washed, counted using a BioRad TC10
automated cell counter, and resuspended in complete tissue
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6 cells/ml. Ten ml
hanging drops were generated as described above and incubated
for 24 hours. Within this time-frame, cells coalescing at the bottom
of the hanging drops formed sheets. Images were captured and
analyzed using IP Lab imaging software. Each image was adjusted
for optimum contrast. Outlines were automatically traced and the
number of pixels within the outlines were calculated. Data points
representing the mean and standard error for aggregate surface
area expressed in pixels (a measure of aggregate compaction) were
calculated from 8–10 aggregates of each cell line.
Assessment of a5 integrin, pan-cadherin expression and
fibronectin secretion by immunoblot analysis
To assess expression of a5-integrin, 25 mg of protein was
separated on a 7% SDS-PAGE gel under non-reducing conditions
and blotted to PVDF membranes using standard protocols. Blots
were blocked in Blotto (5% nonfat dry milk, 0.05% Tween-20, in
PBS) for 1 h, then incubated at 4uC overnight in Blotto with
10 mg/ml rabbit polyclonal antibody against a5 integrin (Milli-
pore, Billerica, MA). For pan-cadherin and actin, protein was
separated under reducing conditions and blots were blocked and
incubated in pan-cadherin (CH-19, Sigma, MO) or actin antibody
(Sigma, ST. Louis, MO). Blots were rinsed three times in TBS-
0.2% Tween-20, and incubated at room temperature for 1 h in
either anti-rabbit or anti-mouse IgG-HRP (Thermo Scientific,
Waltham, MA). After three more rinses, blots were developed
using enhanced chemiluminescence and exposed to X-ray film.
Films were scanned using an HP ScanJet 8300 digital scanner and
digital images were analysed using the gel plotting function in
ImageJ. The optical densities (OD) of the bands representing pan-
cadherin expression and their corresponding actin bands were
quantified from three separate experiments. Cadherin expression
was normalized by expressing OD of the cadherin signal by that of
the corresponding actin signal. Mean OD was compared by
ANOVA and Tukey’s Multiple Comparisons Test (MCT).
To assess FN secretion, cells were plated at equal densities in
complete medium containing FN-depleted FBS and either carrier
or FNMA-inducing agents as described above. Serum was
depleted of FN as described previously [31]. After 24 h, cells
and media were collected together, and cells were pelleted by
centrifugation. One hundred ml of tissue culture medium from
each sample was mixed with 100 ml of gelatin-sepharose beads
(GE Healthcare, Piscataway, NJ). Beads and media were rotated
for 30 min at room temperature (RT) then washed five times in
ice-cold PBS, followed by boiling in SDS sample buffer containing
5% b-mercaptoethanol. Samples were analyzed by SDS-PAGE,
followed by immunoblotting with a biotin-conjugated anti-FN
antibody (AB6584, abcam, Cambridge, MA) and streptavidin-
HRP (Pierce, Rockford, IL). Blots were developed as described
above.
Assessment of surface a5b1 integrin expression by flow
cytometry
Cells were detached from near-confluent tissue culture plates
with trypsin/EDTA (TE; Gibco-BRL, NY), washed three times
with ice-cold Hanks’ balanced salt solution (HBSS), and
resuspended in HBSS at a concentration of 1610
7 cells/ml.
One hundred mls were aliquoted in duplicate into centrifuge tubes.
Five mg/ml of anti-integrin antibody (a5/FnR mouse monoclonal
P1D6, Calbiochem, Gibbstown, NJ) was added to one of the
duplicates and tubes were incubated on ice for 30 minutes with
agitation. After two washes with HBSS, cells were re-suspended in
ice-cold HBSS at 1:100 dilution of Alexa-Fluor 488-conjugated
goat-anti-mouse IgG secondary antibody (Invitrogen, Carlsbad,
CA). After 30 minutes, cells were washed twice with HBSS and
analyzed using a Becton-Dickinson FacsCalibur flow cytometer.
Secondary antibody only controls were used to establish gating
parameters.
Blocking of FNMA by the 70 KDa fragment of fibronectin
To assess the effects of the 70 KDa fragment on FNMA by
immunofluorescence, cells were plated into 24-well tissue culture
plates and incubated with 50 mg/ml 70 KDa fibronectin fragment
(Sigma, MO). Matrix was detected as described above. For
hanging drop cultures, cells were suspended at a concentration of
1610
6 cells/ml and 10 ml hanging drops containing 50 mg/ml
70 KDa fragment were formed as described above. Hanging drops
were incubated for 24–48 hours. These aggregates were used for
spreading velocity assays. For compaction assays, cells were
suspended at a concentration of 2.5610
6 cells/ml in 70 KDa-
containing medium and hanging drops were incubated for
24 hours.
Assessment of FNMA by differential solubilization assay
The assemblyofhigh molecular weight FNmultimers(HMWFM)
was assessed using a deoxycholic acid (DOC) differential solubiliza-
tion protocol as previously described [28,32]. Briefly, 3D aggregates
were generated by the hanging drop method either in the absence
and/or presence of Dex and the 70 KDa fragment. After 24 h of
incubation, aggregates were lysed in a DOC lysis buffer (2% sodium
deoxycholate, 0.02 M Tris-HCl, pH 8.8, 2 mM PMSF, 2 mM
EDTA, 2 mM iodoacetic acid, and 2 mM N-ethylmaleimide),
passed through a 26 gauge needle, and centrifuged at 156Gf o r
20 minutes at 4uC. The supernatant containing the DOC soluble
fraction was transferred to a fresh tube. The pellet from the 20-
minute spin, representing the DOC-insoluble fraction, was solubi-
lized using SDS lysis buffer (1% SDS, 25 mM Tris-HCl, pH 8.0,
2 mM PMSF, 2 mM EDTA, 2 mM iodoacetic acid, and 2 mM N-
ethylmaleimide). The insoluble fraction was separated by SDS –
PAGE under non-reducing conditions, the soluble fraction under
reducing conditions. Protein was transferred to PVDF and probed
with an anti-FN antibody (ab6584, Abcam, UK). Blots containing
the soluble fraction were also probed with an anti-actin antibody
(A2066, Sigma, St. Louis, MO) to control for equal loading.
Statistical analysis
Linear regression analysis was used to describe the relationship
between normalized aggregate diameter and time, for the effect of
Dex-treatment on the slope of the velocity curve, and for the
relationship between velocity and aggregate size. In each case, a
correlation coefficient was generated, a Run’s test was used to
determine departure from linearity, and an F test was used to
determine whether the slopes differed significantly. Ten-fifteen
aggregates from each cell line were used to generate the regression
lines. ANOVA and Tukey’s MCT were used to determine
whether significant differences exist i) in dispersal velocity between
the three cell lines, ii) in aggregate size in response to drug
treatment, (iii) to compare the effect of drug treatment and
presence of the 70 KDa fragment on spreading velocity, and (iv) to
compare OD of the cadherin and actin bands in the pan-cadherin
western blot. A p-value,0.05 was considered significant.
Results
Aggregate dispersal velocity assay
Aggregates of U87-MG, LN-229, and U118-MG cells, when
plated on tissue culture plastic in complete medium, adhere and
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dispersal behavior was quantified by measuring the change in
diameter over time. When aggregate diameter was plotted as a
function of time, the relationship appeared to be linear. This was
confirmed by linear regression analysis. As can be seen in Fig. 1B,
the correlation coefficient, r
2, for U87-MG, LN-229, and U118-
MG was 0.995, 0.990, and 0.989, respectively, indicating a high
probability for linearity. This was further confirmed by testing for
departure from linearity by Run’s test, which showed that the lines
were not significantly non-linear (P=0.78, 0.07, and 0.07 for U-
87MG, LN-229, and U-118MG, respectively). The difference
between the slopes was also analyzed by F test and found to be
significant between the 3 cell lines (P,0.0001). We also tested
whether aggregate size correlates with dispersal velocity. Velocity
and size data from all cell lines was combined and subjected to
regression analysis. Fig. S1 shows that the slope of the regression
line is essentially zero (r
2=0.013), indicating that there is no
relationship between aggregate diameter and spreading velocity.
Based on these data, it was possible to calculate aggregate dispersal
velocity from the slope of the regression line. Since dispersal
velocity must also be influenced by cell motility, we asked whether
these cell lines differed in their migration rates. We performed
assays in which equal numbers of cells were plated onto filters
containing 8 mm pores and migrating cells counted after 16 hours
in tissue culture. As can be seen in Fig. S2, all three-cell lines
migrated at the same rate.
Dispersal velocity of aggregates of U87-MG, LN-229, and
U118-MG
As can be seen in Fig. 2, the dispersal velocity of U87-MG cells
is 21.462.9 mm/h whereas that of LN-229 and U118-MG is
lower, at 4.960.6 mm/h and 4.160.6 mm/h, respectively. AN-
OVA and Tukey’s MCT demonstrated statistically significant
differences between the three cell lines (P,0.0001) and specifically
Figure 1. Time-dependent dispersal of aggregates of U87-MG cells. A) Aggregates of U87-MG cells approximately 50 mm in diameter, plated
onto tissue culture plastic and incubated in complete medium under standard tissue culture conditions, spread to a monolayer within 8 hours. This
dispersal can be quantified as spreading velocity by calculating the slope of the line representing the change in normalized aggregate diameter over
time. A time-lapse movie showing aggregate dispersal can be viewed in Movie S1. B) Linear regression analysis of aggregate spreading. The
relationship between normalized aggregate diameter and time was found to be linear for aggregates of all three-cell lines. The red line represents
aggregates of U87-MG cells, whereas the blue and green lines represent LN-229 and U118-MG, respectively. Ten to 15 aggregates were used to
calculate the mean normalized diameters at each time-point. Standard deviation bars are depicted.
doi:10.1371/journal.pone.0024810.g001
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but not between LN-229 and U118-MG (P.0.05). A potential
molecular mechanism underlying the difference in dispersal
velocity was then explored.
Expression of potential regulators of aggregate dispersal
velocity
Previous studies have shown that aggregate dispersal is a
competitive outcome between cell-cell cohesion and cell-substra-
tum adhesion [33]. In our model, the substrate is kept constant.
Accordingly, differences in dispersal velocity must be attributable
to differences in cell-cell cohesion. We therefore asked whether
these three cell lines expressed different levels of cell surface
adhesion proteins that could account for differences in their
dispersal velocities. A possible difference in cadherin expression
was assessed by immunoblot analysis using a pan-cadherin
antibody. Fig. 3A shows that cadherin expression relative to actin
is similar for all three cell lines. We then quantified optical density
of the cadherin bands normalized to actin and compared the
normalized data from three experiments by ANOVA and Tukey’s
MCT. No difference in expression was detected (Fig. 3B). a5b1
integrin-fibronectin interaction [27] and it’s regulation of FNMA
[28] has previously been shown to mediate indirect cell-cell
cohesion in 3D aggregates. Accordingly, these three cell lines were
assessed for their ability to assemble fibronectin into a matrix. As
can be seen in Fig. 4A, high dispersal velocity U87-MG cells
appear to lack the ability to assemble a matrix as compared with
the slower-dispersing LN-229 and U118-MG cell lines. This was
confirmed by immunoblot analysis. Using a DOC differential
solubilization assay, we show that U87-MG cells are deficient in
the expression of high molecular weight fibronectin multimers as
compared to LN-229 and U118-MG cells. Moreover, there also
appears to be a difference in the presence of fibronectin in the
soluble fraction. This likely represents a difference in their capacity
to bind fibronectin at the cell surface (Fig. 4B). This difference in
capacity for FNMA was not due to differences in a5b1 integrin
expression, since cell lines expressed similar levels as demonstrated
by significant overlap of histograms as in flow cytometry
experiments (Fig. 4C). This was confirmed by comparing mean
fluorescence intensity (MFI) of the normalized histogram data for
U87-MG, LN229 and U118-MG cells. As can be seen in Fig. 4D,
MFI values of five separate experiments are similar for U87-MG
and U118-MG cells, suggesting that these lines express similar
levels of a5b1 integrin. MFI values of LN229 cells are lower,
indicating that a5b1 integrin expression by the three cell lines is
variable.
FNMA can be regulated by drug treatment and can
influence aggregate compaction
Gliomas are known to exhibit high Ras activity [34] and this has
been shown to impede FNMA [35]. We asked whether restoring
FNMA would decrease dispersal velocity. This was accomplished
Figure 2. Aggregate dispersal velocity of 3-glioblastoma cell
lines. This bar graph depicts the spreading velocities of aggregates of
U87-MG, LN-229, and U118-MG cells. Data sets included sample sizes of
14, 10, and 11 aggregates, respectively. Aggregate spreading was
monitored over an 8-hour period. Movies of the spreading were
captured and images at various time points were analyzed. Normalized
aggregate diameter was plotted as a function of time, generating a
slope, which was used to calculate spreading velocity. As can be seen
here, the spreading velocity of aggregates of U87-MG cells is
considerably faster than that of either LN-229 or U118-MG (ANOVA,
p,0.0001 and Tukey’s MCT).
doi:10.1371/journal.pone.0024810.g002
Figure 3. Assessment of pan-cadherin expression by glioma
cells. A) Overall cadherin expression by the three cell lines was assessed
by immunoblot analysis using a pan-cadherin antibody (clone CH-19,
Sigma). Bands, corresponding to the molecular weight of cadherin, are
evident. Actin was used as a loading control. B) Quantification of
cadherin expression by densitometric analysis. Optical density (OD) of
cadherin bands was measured in triplicate as described in the Methods
section. These measurements were then normalized by expressing OD
of the cadherin signal by that of the corresponding actin signal. Here,
the average normalized cadherin OD of the three cell lines is compared.
No difference in cadherin expression was detected (ANOVA, p.0.05).
doi:10.1371/journal.pone.0024810.g003
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FNMA by glioma cells. Cells were plated at equal density and incubated for 24 hours, whereupon they were stained with an anti-fibronectin antibody
and an Alexa-568-conjugated secondary IgG. Cell nuclei were counterstained using Syto-16 live-cell nuclear stain. Images from green and red
channels were captured, pseudo-colored, and merged in IP lab. Nuclei are depicted in green and fibronectin matrix is depicted in red. B) Biochemical
analysis of FNMA by differential solubilization assay and immunoblot analysis. The assembly of high molecular weight fibronectin multimers
(HMWFM) by U87-MG, LN-229, and U118-MG cells was assessed using DOC differential solubilization assay. DOC-soluble and insoluble fractions were
separated by SDS-PAGE and analyzed by immunoblotting using an anti-fibronectin antibody. Actin in the soluble fraction was used as loading
control. C) Analysis of cell surface a5b1 integrin expression by flow cytometry. Cells were trypsinized from near-confluent tissue culture plates,
washed, and incubated with a mAb specific for the extracellular domain of a5 integrin, followed by incubation with a FITC-conjugated secondary
antibody. The control panel (left) represents cells incubated with secondary antibody only. The right panel represents cell surface expression of a5
integrin. D) Comparison of a5b1 integrin expression by measuring mean fluorescence intensity (MFI). Cells were incubated in either IgG-FITC or in
anti-a5b1 integrin antibody and IgG-FITC as described in Materials and Methods. Cells were appropriately gated and statistical analyzed using
CellQuest software to calculate MFI values for controls and their matched samples. The MFI values of controls were subtracted from the MFI values of
their matched samples, yielding a net MFI value for each cell line. Five separate experiments were performed using exact cytometer settings. The MFI
data were averaged and mean MFI were compared by t-test or ANOVA and Tukey’s MCT. MFI of U87-MG and U118-MG were statistically identical
(ANOVA, P,0.0001, Tukey’s MCT, p.0.05). MFI of LN229 was lower than that of either U87-MG or U118-MG (ANOVA, p,0.0001, Tukey’s MCT,
p,0.001).
doi:10.1371/journal.pone.0024810.g004
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demonstrated to restore FNMA, then assessing influence on
aggregate compaction and dispersal velocity. Fig. 5A shows that
for U87-MG cells, Dex and GA significantly increased fibronectin
matrix as compared to controls. A different effect was observed
when U118-MG cells were treated. In that case, only GA
appeared to significantly upregulate FNMA. In previous studies,
we showed that restoring FNMA in CHO cells resulted in
increased compaction and aggregate cohesion [27]. We therefore
asked whether drug treatment and the attendant increase in
fibronectin matrix influence compaction of these brain tumor cell
lines. Fig. 5B represents a compaction assay for control and drug-
treated U87-MG cells. Analysis by ANOVA and Tukey’s MCT
shows that drug treatment significantly decreased aggregate size
(P,0.0001). Specifically, treatment with Dex, MEKi, and GA
resulted in tighter and more compact sheets than treatment with
control vehicles H2O and DMSO (P,0.001). Dex appeared to be
more effective in promoting compaction than the other 2 agents
(P,0.001). In contrast, treatment with MEKi and GA resulted in
similar compaction profiles (P.0.05). Interestingly, aggregate
compaction appears to correlate with the amount of fibronectin
matrix. Aggregates in which matrix was significantly upregulated,
such as those treated with Dex or GA, compacted to a greater
degree than those in which matrix was reduced, such as those
treated with MEKi or carrier controls. Of note, is that drug
treatment and restoration of FNMA did not involve upregulation
of a5b1 integrin or increased FN secretion, since integrin
expression and secretion appeared to be unaffected as determined
by immunoblot analysis (Fig. 5C). Moreover, the drug-mediated
increase in compaction does not appear to involve increased
cadherin expression, since immunoblot analysis using a pan-
cadherin antibody showed that cadherin levels were also
unaffected by drug treatment (Fig. 5C). We also performed assays
to determine whether drug treatment altered cell migration as this
could influence spreading velocity. We treated cells with either
carrier or drugs and performed migration assays as described in
Fig. S3. No difference was observed between carrier-only controls
and cells treated with either Dex or MEKi. We did observe a
significant decrease in migration of GA-treated cells (Fig. S3).
However, we also noted that GA-treatment substantially increased
cell size from 16 mm to nearly 30 mm, making it more difficult for
cells to squeeze through the 8 mm pores of the filter chamber
within the time-frame of the experiment. This change in cell size
could, in principle, explain why fewer GA-treated cells migrated
through the filter. Accordingly, it is unlikely that drug treatment
reduced dispersal velocity by influencing cell migration, but rather,
that drug-treatment inhibited the ability of cells to detach from the
mass.
Drug treatment significantly reduces spreading velocity
The Dex-mediated upregulation of FNMA observed for highly
dispersive U87-MG cells significantly reduced the slope of the
regression line. Fig. 6A shows that Dex-treatment reduced the
slope from 0.30960.007 to 0.119860.0104 and that the difference
in slope was significant (F test, P,0.0001). The correlation
coefficient, r
2, for the regression lines was 0.99 and 0.95 for
untreated and Dex-treated aggregates, respectively, demonstrating
a direct linear relationship between normalized diameter and time.
This was confirmed by Run’s test, which showed that the
regression line was not significantly non-linear (P,0.0714). A
reduction in the slope of the regression line signifies a decrease in
aggregate spreading velocity. This decrease in spreading velocity is
associated with an increase in cell-cell contact between cells
dispersing from the aggregate mass. Fig. 6B shows that after 8-
hours in culture, cells at the dispersal margin tend to maintain little
contact as they disperse, whereas those of aggregates treated with
Dex maintain contact as they spread. Movies of the spreading
process with and without Dex can be viewed in Movies S1 and S2,
respectively. As can be seen, untreated aggregates of U87-MG
tend to disperse as isolated cells (Movie S1), whereas Dex-treated
aggregates appear to spread out as an interconnected sheet (Movie
S2).
Since Dex is known to have pleiotropic effects, other agents
known to upregulate FNMA were assessed for their ability to
reduce spreading velocity. As shown in Fig. 6C, Dex significantly
reduced the spreading velocity of U87-MG cells from
21.462.0 mm/h to 7.561.4 mm/h (Tukey’s MCT, P,0.001).
GA had a similar effect, reducing spreading velocity from
18.260.6 mm/h for DMSO controls to 8.860.6 mm/h (Tukey’s
MCT, P,0.001). In contrast, treatment with MEKi did not
significantly reduce velocity (Tukey’s MCT, P.0.05). A similar
pattern was observed for U188-MG aggregates. Here, GA also
significantly reduced spreading velocity (Tukey’s MCT, P,0.05),
whereas MEKi appeared to have no effect (Tukey’s MCT,
P.0.05). Dex treatment also did not appear to significantly
reduce aggregate spreading velocity when the data were
compared by ANOVA and Tukey’s MCT. However, when the
spreading velocity of Dex-treated aggregates was compared only
to the H2O carrier control and analyzed by Student’s t-test, the
difference in spreading velocity was significant (P=0.015).
Strictly speaking, while analysis by ANOVA/Tukey’s MCT is
statistically more robust, results of the t-test analysis better reflects
direct observation and, therefore, may be more biologically
relevant.
Effects of the 70 KDa fibronectin fragment on matrix
assembly and aggregate compaction
To establish a mechanism of action of FNMA, we blocked
matrix assembly after drug treatment and explored effects on
spreading velocity of aggregates of U87-MG cells. Aggregates
were generated in the presence of a 70 KDa fragment of
fibronectin, which has previously been shown to block FN
assembly [36]. The amount of 70 KDa fragment required to
block matrix formation was determined by generating aggregates
in the presence of either 25 mg/ml or 50 mg/ml 70 KDa and
assessing effects on matrix assembly by immunoblot analysis.
Fig. 7A shows that Dex treatment increases the amount of
insoluble matrix detected and that the presence of the 70 KDa
fragment significantly reduces matrix in a dose-dependent
manner. Presence of the 70 KDa fragment had no effect on
the amount of soluble fibronectin. Similar results were obtained
when FNMA was assessed by immunofluorescence. Fig. 7B
shows that addition of 50 mg/ml of 70 KDa fragment to both
untreated and Dex-treated cells results in a reduced, more
punctate, matrix as compared to cells incubated in absence of
the blocking agent. Results of aggregate compaction assays
demonstrate that Dex-treated aggregates compacted into tight
spheres, whereas inclusion of the 70 KDa fragment gave rise to
flat sheets of cells. As expected, addition of the 70 KDa fragment
to untreated U87-MG cells had no effect. Having demonstrated
that the 70 KDa fragment can block Dex-mediated matrix
assembly and aggregate compaction, we explored effects on
spreading velocity.
Blocking FNMA rescues spreading velocity
Spreading velocity was assessed for aggregates that were either
untreated, or treated with Dex and incubated in either the absence
or presence of 50 mg/ml of the 70 KDa fragment. Fig. 7C shows
Inhibition of Glioma Dispersal by Fibronectin
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17.861.0 mm/h to 5.0260.4 mm/h (Tukey’s MCT, P,0.001),
but that inclusion of the 70 KDa fragment rescues the spreading
velocity to 15.560.5 mm/h, a level approximating that of
untreated aggregates (Tukey’s MCT, P.0.05). These data support
a direct role for FNMA during aggregate dispersal.
Figure 5. Reastoration of FNMA promotes compaction of glioma cells. A) Restoration of FNMA by Dexamethasone, MEK inhibitor, and
Geldanamycin. Cells were plated at equal densities and incubated for 24 hours in the presence of Dexamethasone, MEK inhibitor, Geldanamycin, or
carrier-only controls. FNMA by U87-MG and U118-MG was assessed by immunofluorescence as previously described. Fibronectin matrix was detected
using anti-fibronectin antibody (ab6584) and Alexa-568-conjugated secondary IgG and is depicted in red. Nuclei were stained with Syto-16 live-cell
nuclear stain and are depicted in green. Dex and GA appear to be most effective in restoring FNMA in both lines. B) Restoration of FNMA results in
aggregate compaction. Untreated and drug-treated U87-MG cells were placed in hanging drop culture and incubated for 24 hours, whereupon
aggregate size was measured as previously described. Depicted are mean aggregate size in pixels, with corresponding standard error. Note the
marked compaction of aggregates treated with Dex, MEKi, or GA relative to carrier controls (water and DMSO). C) Immunoblot analysis of a5 integrin
and pan-cadherin expression and of FN secretion in response to drug treatment. Antibodies specific for a5 integrin, secreted fibronectin, or pan-
cadherin were used to determine whether drug treatment altered expression or secretion levels. Immunoblot analysis reveals that drug treatment
does not appear to upregulate the expression of either a5 integrin nor of any cadherin recognized by the CH-19 pan-cadherin antibody. FN secretion
also appears to be unaffected by drug treatment. Depicted, are protein levels relative to actin, which was used as loading control.
doi:10.1371/journal.pone.0024810.g005
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The aggregate dispersal velocity assay
Spheroid formation by U87-MG, LN-229, and U118-MG is
well-documented [21,37] and can be best described as a behavior
typical of viscoelastic liquids [38]. This liquid-like behavior can be
exploited to measure key properties that have previously been
shown to significantly influence tumor invasion. One such
property, tumor surface tension, has been shown to be inversely
proportional to invasive capacity [19,21,39]. Another such
property, tumor dispersal velocity, was measured here. To
measure dispersal velocity we assessed the rate of spreading, or
‘‘wetting’’, of a solid substrate by a liquid aggregate. Adhesive
forces between a liquid and solid cause a liquid drop to spread
across the surface. Cohesive forces within the liquid cause the drop
to ball up and avoid contact with the surface [30]. In cellular
aggregates, these forces are represented by cell-ECM adhesion-
and cell-cell cohesion mechanisms, respectively. In order to
disperse, tumor cells must overcome forces holding them to the
tumor mass and must also acquire sufficient traction to the
substrate onto which they disperse. We plated aggregates
composed of malignant glioblastoma cells onto tissue culture
plastic in complete medium and observed that within 8 hours,
aggregates had nearly spread to a monolayer. The spreading was
linear and size-independent allowing us to directly measure
spreading velocity.
Dispersal velocity of three glioblastoma cell lines
The cell lines used in this study have been extensively
characterized and used for decades. All were derived from tumors
that originally had been classified as astrocytoma grade IV/
glioblastoma [40]. Despite the similarity in pathologic grade, these
three lines have been shown to possess different biomechanical
properties that can markedly influence their invasive behavior. For
example, aggregates of U87-MG cells were found to be less
cohesive than those of LN-229 or U118-MG and that cohesion is
inversely proportional to their invasive capacity [41]. In this study
we showed that dispersal velocity also differed markedly;
aggregates of U87-MG cells dispersing much more quickly than
those of LN-229 and U118-MG. Interestingly, dispersal velocity
appears to be inversely proportional to aggregate cohesion,
consistent with the concept that it may be possible to decrease
brain tumor dispersal by increasing the overall cell-cell cohesion of
a tumor, effectively making it more difficult for cells to escape the
tumor mass. Since dispersal is a hallmark of glioma, reducing
dispersal could be of therapeutic benefit. Understanding the
molecular mechanisms underlying tumor dispersal is fundamental
to devising effective therapeutic strategies.
Molecular determinants of glioblastoma dispersal
The difference in dispersal velocity between glioblastoma cells
suggests that differences may exist in the expression or function of
molecules controlling cell-cell cohesion or cell-ECM adhesion. In
this study, we explored whether differences in cadherin expression
could potentially explain differences in dispersal velocity. Immu-
noblot analysis using a pan-cadherin antibody failed to reveal any
differences in cadherin expression between lines. Interestingly, a
marked difference in integrin function vis a vis FNMA was
Figure 6. Effects of drug treatment on aggregate spreading
velocity. A) Dex treatment significantly reduces the slope of the
regression line. Aggregate spreading assays were performed using
untreated and Dex-treated aggregates of U87-MG cells. Slopes were
found to be significantly different (F-test, P,0.0001), with untreated
aggregates having a steeper slope than that of their Dex-treated
counterparts. B) Dex treatment promotes cell-cell contact during
aggregate spreading. Depicted are phase-contrast images of control
and Dex-treated aggregates of U87-MG glioma cells after 8 hours of
incubation. Dex treatment markedly reduces spreading and appears to
promote cell-cell cohesion at the advancing cell front. C) Spreading
velocity of control and drug-treated aggregates. Spreading velocity of
aggregates of U87-MG (solid bars) and U118-MG (hatched bars) was
compared in response to treatment with Dex, MEKi or GA. Treatment by
Dex or GA consistently reduced aggregate dispersal velocity in both cell
lines.
doi:10.1371/journal.pone.0024810.g006
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integrins are currently emerging as a promising target of
anticancer therapy [42]. Integrins most notably associated with
glioma invasion are b1 integrin, which can then pair with several a
subunits including a2, a3, a5, and a6 [43]. avb3 and avb5 are
also over-expressed on both glioma cells and their vasculature
Figure 7. Blocking Dex-mediated FNMA rescues spreading velocity. A) Blocking of FNMA by the 70 KDa fragment of fibronectin. Aggregates
of U87-MG cells generated and incubated in the absence and/or presence of the 70 KDa fragment were assessed for FNMA by differential
solubilization assay. DOC-soluble and insoluble fractions were separated by SDS-PAGE and analyzed by immunoblotting using an anti-fibronectin
antibody. Actin in the soluble fraction was used as loading control. As expected, Dex-treatment significantly increased the amount of soluble
fibronectin and high molecular weight fibronectin multimers (HMWFM). Addition of the 70 KDa fragment had no effect on soluble fibronectin but
significantly reduced the amount of insoluble FN matrix, represented here by a specific band of molecular weight .220 KDa. Knock-down of the FN
matrix was more pronounced in aggregates generated and incubated in 50 mg/ml of the 70 KDa fragment. B) Blocking Dex-induced matrix assembly
influences aggregate compaction. U87-MG cells were plated either in conventional 2D culture (IF panel) or in 3D hanging drop culture (compaction
panel) in the absence and/or presence of Dex and 70 KDa fragment. Cells in 2D culture were incubated in anti-fibronectin antibody followed by an
Alexa-488-conjugated secondary antibody. Fibronectin matrix is depicted in green. DAPI was used to label nuclei, here depicted in blue. Inclusion of
the 70 KDa fragment in both untreated and Dex-treated aggregates alters the appearance of the matrix from one in which long fibers extend
between cells to a more punctate pattern. A corresponding change in compaction was also noted; Dex-treated cells tending to form less compact
aggregates when incubated in the presence of the 70 KDa fragment. C) Blocking Dex-induced fibronectin matrix assembly rescues aggregate
spreading velocity. The spreading velocity of aggregates prepared in the presence of a combination of Dex and the 70 KDa fragment was greater
than that of aggregates generated in Dex-containing medium alone and approached the spreading velocity of untreated aggregates.
doi:10.1371/journal.pone.0024810.g007
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facilitating cell motility and migration. This study describes a
different role, one in which a5b1 integrin function acts to
discourage cell migration by increasing the overall cohesion of the
tumor mass. In this view, a5b1 integrin–fibronectin interaction
acts as a cellular glue, effectively connecting cells in 3D aggregates
to one-another, thus discouraging detachment. We have previ-
ously reported that integrin-mediated cohesion is fibronectin-
dependent, but more critically, that the fibronectin must be
assembled into a fibrous matrix in order for aggregates to fully
express their potential cohesive intensity [28]. Moreover, recent
studies revealed that both integrin expression levels and the
amount of available fibronectin must be optimized to fully support
formation of a fibronectin matrix [44]. Thus, differences in a5
integrin expression or in fibronectin secretion could be responsible
for differential capacity for FNMA between these three cell lines.
This, however, is not the case since these lines appear to 1) express
similar levels of surface a5 integrin as assessed by flow cytometry,
and 2) secrete similar levels of fibronectin, as assessed by
immunoblot analysis (data not shown). Therefore, the differences
in the capacity for FNMA in the absence of differences in a5
integrin expression or fibronectin secretion by these cell lines,
suggests a possible defect in a5b1 integrin function. Gliomas are
known to exhibit high Ras activity [34] leading to constitutively
active ERK, which has been shown previously to impede FNMA
[35]. Inhibition of ERK MAP kinase activation by Dex, a
synthetic glucocorticoid steroid commonly used to treat brain
tumor related intracranial edema, enhanced FNMA in deficient
cell lines [35]. We had previously shown that Dex treatment of
U87-MG cells resulted in increased cohesion as measured by TST
and that this was correlated with a marked decrease in invasive
potential [21]. We therefore asked whether this increase in
cohesion was due to restored capacity for FNMA and whether this
would have an effect on dispersal velocity.
Restoring FNMA significantly reduces aggregate
dispersal velocity of glioma cells
We treated cells with Dex, MEKi, or GA, agents previously
demonstrated to reactivate FNMA in cells defective in this process.
Treatment with any of these agents restored FNMA by glioma
cells and promoted aggregate compaction but not all to the same
extent. MEKi, for example, stimulated FNMA to a lesser extent in
both U87-MG and U118-MG, whereas Dex and GA had a
greater effect. This was directly reflected in their spreading
velocities. The effects of the drugs were more pronounced in
highly dispersive U87-MG cells than in U118-MG, suggesting that
restoration of FNMA may be more efficacious in controlling
dispersal velocities of more highly aggressive cell lines or tumors.
Restoration of FNMA was independent of de novo expression of
a5 integrin or of increased fibronectin secretion, suggesting that
treatment resulted in restoration of a5 integrin function rather
than by genetically modifying expression of the molecules
controlling the process. Previous studies from our laboratory have
shown that cadherin expression is directly correlated with
aggregate cohesion [45] and that this, in turn, is inversely
proportional to aggregate spreading rate [33]. Accordingly, we
also explored the possibility that drug treatment, in addition to
activating FNMA, may also have resulted in the upregulation of
cadherin expression. This was not the case since cadherin
expression appeared to be unaffected by drug treatment.
Effectively, Dex treatment reduced spreading velocity by shifting
the balance of forces mediating spreading to favor cell-cell
cohesion. Restoring FNMA reduced dispersal velocity by increas-
ing the overall cohesion of the tumor, thus reducing the
detachment of cells from the tumor mass.
Blocking Dex-induced FNMA with the 70 KDa fragment
of fibronectin rescues dispersal velocity
In order to address whether the drug-induced increase in
FNMA is functionally responsible for the observed decrease in
aggregate spreading velocity, we performed assays in which
FNMA was induced by Dex treatment. We then measured
spreading velocity in the absence or presence of the amino-
terminal 70 KDa fragment of fibronectin. Because this fragment
binds reversibly to cell surfaces with the same affinity as the native
protein, it blocks incorporation of fibronectin into a fibrous matrix
[36]. In principle, incubating aggregates in Dex and in 70 KDa
fragment, should block matrix assembly and thus rescue spreading
velocity. We show that U87-MG cell aggregates generated in the
presence of Dex and 50 mg/ml 70 KDa fragment exhibit a
markedly reduced capacity to assemble fibronectin and that
whatever matrix did assemble did so in a punctate pattern rather
than as fibers. This apparent reduction in FNMA resulted in a
significant rescue of dispersal velocity similar to that of untreated
controls. Collectively, these data provide evidence that differences
in dispersal velocity or aggregate cohesion between glioblastoma
cell lines is their capacity for FNMA. To our knowledge, this is the
first demonstration that a5b1 integrin-fibronectin interaction can
function as a dispersal suppressor in glioblastoma cells.
Whether FNMA plays a role clinically has yet to be determined.
One recent study using human brain tumors and an animal model
of glioma invasion showed that down-regulation of FNMA can
render glioma cells more resistant to chemotherapy [46]. Our
study suggests that increasing FNMA may in fact be protective by
discouraging cell detachment from the tumor mass. These two
points of view are not incompatible. There may in fact be an
optimum level of FNMA that could still sensitize cells to
chemotherapy while also discouraging escape of those cells from
the tumor mass. Clearly no single factor can be predictive of
clinical outcome. However, it is equally clear that dispersal of
tumor cells is fundamentally linked to a poor prognosis. We
showed that despite the fact that these cell lines were derived from
tumors that were all staged as GBM, they possess distinctly
different dispersal velocities that appear to correlate with their
ability to assemble fibronectin into a matrix. Tumors composed of
cells that possess this ability and are therefore more cohesive,
would disperse more slowly or to a lesser degree. Since dispersal is
a hallmark of gliomas, these differences could potentially explain
why some patients diagnosed with glioblastoma may live for years,
rather than months. It is also possible that the observed differences
in dispersal velocity between these cell lines are purely artifact of
tissue culture and that such differences do not exist in human brain
tumors. To address this question would require a comprehensive
assessment of FNMA in human brain tumor samples or in freshly
isolated primary cell lines, followed by measurements of dispersal
velocity, and ultimately, connection of this and other parameters,
to clinical outcome We showed that Dex and other agents that
upregulate matrix assembly can reduce dispersal velocity. While
Dex is routinely used to treat brain tumor-related intracranial
edema, we do not suggest that Dex or the other drugs specifically
used in this study are of clinical relevance as potential therapy.
Rather, we suggest that conceptually, the dispersal velocity assay
may represent a platform for testing agents aimed at reducing
dispersal by increasing aggregate cohesion, whether by up-
regulating FNMA or by some other mechanism. An approach to
limit dispersal and elucidation of the molecular determinants
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Supporting Information
Figure S1 Spreading velocity is independent of aggre-
gate size. We tested whether aggregate size could influence
spreading velocity by pooling all data and comparing the diameter
of each aggregate to its matched spreading velocity. The line
describing this relationship has a slope of 20.021. An F-test
revealed that the slope of the line is not significantly non-zero
(P,0.554). These data indicate that velocity is independent of
aggregate size.
(TIF)
Figure S2 Transfilter migration of U87-MG, LN-229 and
U118-MG cells. We compared the migration rates of the three
cell lines by plating 1610
4 cells into the top of an 8 mm transfilter
chamber and counting the number of cells that migrated to the
underside of the filter after overnight culture. Cells were plated
onto 2 filters for each cell line. Cells remaining in the upper
chamber were wiped off using a cotton swab. Those on the bottom
aspect of the filter were stained using SYTO-16 nuclear stain. Four
images, representing almost all of the filter surface area, were
collected for each filter. Images of the cell nuclei were captured
and images were analyzed using ImageJ. The number of migrating
cells/field were compared by ANOVA and Tukey’s MCT. No
difference was detected (p.0.05).
(TIF)
Figure S3 Migration of U87-MG cells in response to
drug-treatment. We compared the transfilter migration rates of
untreated and drug-treated U87-MG cells to determine whether
drug treatment significantly influenced cell motility. Analysis of the
data by ANOVA and Tukey’s MCT revealed that Dex and MEKi
treatment did not significantly alter migration (p.0.05). However,
GA appeared to markedly reduce the number of cells that were
able to migrate through the 8 mm pores of the filter. We also noted
that treatment by GA significantly increased cell size from an
average of 17 mm for the carrier control and Dex or MEKi-treated
cells to approximately 30 mm. This increase in size could, in
principle, significantly impact the ability of cells to migrate
through the 8 mm pores of the trans-well filter.
(TIF)
Movie S1 Time-lapse movie of untreated aggregates of
U87-MG cells. Aggregates were plated on tissue culture plastic in
complete CO2-independent medium and incubated on a heated
stage of an inverted microscope. Images were captured every five-
minutes for 8-hours. A time-lapse movie of aggregate spreading
was generated by importing the Tiff images into Quicktime.
Untreated aggregates of U87-MG tend to spread as single cells.
(MOV)
Movie S2 Time-lapse movie of Dex-treated aggregates
of U87-MG cells. Cells were treated with 10
26 M Dex for
16 hours and aggregates were generated as previously described.
Aggregates were plated on tissue culture plastic in complete CO2-
independent medium containing 10
26 M Dex, and incubated on a
heated stage of an inverted microscope. Images were captured
every five-minutes for 8-hours. A time-lapse movie of aggregate
spreading was generated by importing the Tiff images into
Quicktime. Dex-treatment appears to increase cell-cell cohesion at
the advancing cell front and aggregates appear to spread as sheets.
(MOV)
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